GEN HOUSE

GEN HOUSE is located in Suzhou Industrial Park, a hub of cultural richness and innovation for pharmaceutical enterprises. It is a biotechnology company focused on the development of globally leading small-molecule anti-cancer drugs. The company's management team has years of experience in corporate management, new drug research and development, and clinical medical research, with a commitment to overcoming "undruggable" targets and focusing on original innovation. GEN HOUSE is dedicated to building a distinctive R&D system for innovative drugs, establishing a structure-activity relationship research platform based on structural biology, an early drug screening platform based on target research, and a preclinical evaluation platform covering efficacy, metabolism, and safety studies. This has led to a product pipeline centered on targeted anti-cancer therapies. Thanks to its comprehensive strategic planning and implementation capabilities in innovative drug R&D, GEN HOUSE successfully signed an overseas rights transfer agreement for the SHP2 inhibitor GH21 with HUYA Bioscience International, bringing China's innovative drugs to the global market.